KalVista Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 62 to 90.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against all other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating of above 80 at the beginning of a new run.
KalVista Pharmaceuticals is now considered extended and out of buy range after clearing an 11.45 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
KalVista Pharmaceuticals showed 0% EPS growth last quarter, while sales growth came in at 0%. Keep an eye out for the company's next round of numbers on or around Jul. 8.
KalVista Pharmaceuticals earns the No. 166 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Anbio Biotechnology are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
